Mentalisation-Based Treatment versus care-as-usual in the treatment of severe borderline personality disorders.

Gepubliceerd: 21-01-2010 Laatst bijgewerkt: 19-03-2025

Mentalisation-Based Treatment (MBT) for patients with severe Borderline Personality Disorders will result in a better clinical outcome compared with care as usual.

Ethische beoordeling	Positief advies
Status	Werving nog niet gestart
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON23439

Bron
NTR

Aandoening

Severe Borderline Personality Disorders

Ondersteuning

Primaire sponsor: 1. Arkin Amsterdam, The Netherlands

Arkin
Afdeling Onderzoek Arkin Academy
Overschiestraat 65
1062 XD AMSTERDAM

2. GGZ inGeest, Amsterdam, The Netherlands
GGZ inGeest
Postbus 74077
1070 BB AMSTERDAM

3. De Viersprong, Halsteren, The Netherlands

PTC De Viersprong
Postbus 7
4660 AA HALSTEREN
Nederland

4. Vrije Universiteit, Faculteit der Aard- en Levenswetenschappen Ontwikkelingsgenetica, Amsterdam, The Netherlands

Vrije Universiteit Amsterdam
Faculteit der Aard- en Levenswetenschappen
Ontwikkelingsgenetica
Postbus 7161
1007 MC AMSTERDAM
Overige ondersteuning: ZonMw, Nederlands Organisatie voor gezondheidsonderzoek en zorginnovatie, , Den Haag, The Netherlands

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

The frequency and severity of manifestations of BPD as measured with the BPDSI. The BPDSI is a semi structured interview, developed to assess short-term BPD pathology as defined by DSM-III-R/DSM-IV criteria (APA, 1987, 1994).

Toelichting onderzoek

Achtergrond van het onderzoek

Objective

To examine the effectiveness/cost-effectiveness of Mentalisation-Based Treatment (MBT) for patients with severe Borderline Personality Disorders (BPD).

Design

A randomised controlled trial comparing standard psychiatric care with MBT. After a baseline measurement, patients will be followed up every 6 months for a total of 36 months.

Study populations/datasets

Patients with severe BPDs as determined with the SCID-II and a minimum score of 25 on the Borderline Personality Disorder Severity Index (BPDSI).

Intervention

The aim of MBT is to improve patients' ability to mentalise. The inability to mentalise, particularly in emotional interactions, is thought to be one of the main problems in severe borderline personality disorder. MBT is given in group sessions and individual sessions. The treatment is delivered by a multidisciplinary team in two phases of 18 months each. During the first treatment phase, patients receive intensive day treatment five days a week. In the second treatment phase, after-care treatment is provided: one individual session of psychotherapy and one group session of psychotherapy weekly.

Outcome measures

The primary clinical outcome measure is the frequency and severity of manifestations of Borderline Personality Disorder as measured with the BPDSI. Secondary outcome measures include a. number of suicide acts, b. self-mutilation, c. depression, d. subjective experiences of symptoms, e. social and interpersonal functioning, f. personality functioning, g. quality of life, h. treatment adherence.

Sample size calculation/data analysis

With two groups of 54 patients, an alpha of 0.05,an effect size of 0.9 can be detected with a statistical power of >90%. Analysis will be performed according to the intention to treat principle.

Economic evaluation

The economic evaluation will be conducted from a societal perspective with a time horizon of 36 months. Resource use and occupation-related costs will be measured using the TiC-P and PRODISQ, and will be valued using Dutch standard prices. Bootstrapping will be used to estimate the uncertainty surrounding these ratios.

Doel van het onderzoek

Mentalisation-Based Treatment (MBT) for patients with severe Borderline Personality Disorders will result in a better clinical outcome compared with care as usual.

Onderzoeksopzet

Baseline measurements will be taken after randomisation and follow-up measurements will be conducted 6, 12, 18, 24, 30 and 36 months after the baseline measurement.

Onderzoeksproduct en/of interventie

The concept of mentalising was developed in attachment research, psychoanalytical concepts, Theory
of Mind and neurobiological research. Mentalisation can be described as the ability to understand your
own and others' mental state on the basis of overt behaviour. The inability to mentalise, particularly in
emotional interactions, is considered to be one of the main problems in borderline personality disorder,
resulting in emotional instability, impulsive behaviour, and vulnerability in interpersonal and social
interactions. MBT was developed by Peter Fonagy and Anthony Bateman (6,7,15,16) with the aim of
improving patients' ability to mentalise, specifically in situations in which this is difficult for the patient.

MBT is given in group sessions and individual sessions. The treatment comprises two phases, each
taking 18 months. During the first treatment phase, patients receive intensive partial hospitalization
treatment, five days a week. In the second phase, after-care treatment is provided, consisting of one
session of individual psychotherapy and one session of group psychotherapy weekly. This treatment is
relatively expensive and therefore it is justified to do a state of the art cost effectiveness study as
proposed in this application. In the study by Bateman and Fonagy such an extensive cost analysis was
not performed.

Contactpersonen

Publiek

Arkin
Jack J.M. Dekker
Klaprozenweg 111
Amsterdam 1033NN

The Netherlands

Wetenschappelijk

Arkin
Jack J.M. Dekker
Klaprozenweg 111
Amsterdam 1033NN
The Netherlands

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

A severe BPD on the basis of standardised criteria for borderline personality disorder and assessed with the Dutch version of the Structured Clinical Interview for DSM-III-R (SCID-II) (13), and the Borderline Personality Disorder Severity Index (BPDSI) (14). Patients must meet the criteria for borderline personality disorder as determined with the SCID-II and have a total score on the BPDSI of at least 24, indicating a severe BPD. Patients with co-morbid personality disorders will not be excluded.

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

Patients will be excluded if they meet one of the following criteria:

1. Schizophrenia, as determined with the SCID-I;

2. Bipolar disorder, as determined with the SCID-I;

3. Substance addiction requiring specialist treatment;

4. Organic brain disorder;

5. Mental impairment (IQ < 80);

6. Inadequate mastery of the Dutch language.

Onderzoeksopzet

Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Parallel
Toewijzing:	Gerandomiseerd
Blindering:	Dubbelblind
Controle:	Geneesmiddel

Deelname

Nederland

Status:	Werving nog niet gestart
(Verwachte) startdatum:	01-03-2010
Aantal proefpersonen:	108
Type:	Verwachte startdatum

Ethische beoordeling

Positief advies

Datum:	21-01-2010
Soort:	Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

ID: 33534
Bron: ToetsingOnline
Titel:

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL2058
NTR-old	NTR2175
CCMO	NL26308.097.09
ISRCTN	ISRCTN wordt niet meer aangevraagd.
OMON	NL-OMON33534

Resultaten

Samenvatting resultaten
N/A